CDKN2A and idiopathic pulmonary fibrosis: In summary, while the identification of novel therapeutic targets for IPF, such as SPP1, CCL2, and CDKN2A, offers promising treatment options, several critical issues must be addressed before these findings can be translated into clinical practice.